Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) shares saw unusually-strong trading volume on Tuesday. 1,475,558 shares changed hands during trading, an increase of 14% from the previous session’s volume of 1,289,672 shares. The stock last traded at $10.2830 and had previously closed at $11.47.
Analyst Ratings Changes
IMMX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Friday, July 17th. Needham & Company LLC started coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price for the company. Citigroup reaffirmed a “market outperform” rating on shares of Immix Biopharma in a research note on Friday, August 14th. Lifesci Capital started coverage on Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price objective for the company. Finally, Mizuho lifted their target price on Immix Biopharma from $15.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immix Biopharma has a consensus rating of “Moderate Buy” and an average target price of $22.86.
Check Out Our Latest Research Report on IMMX
Immix Biopharma Trading Down 8.6%
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Sell-side analysts expect that Immix Biopharma, Inc. will post -0.73 EPS for the current fiscal year.
Hedge Funds Weigh In On Immix Biopharma
A number of large investors have recently made changes to their positions in IMMX. Legal & General Group Plc acquired a new stake in shares of Immix Biopharma during the second quarter worth approximately $41,000. Compass Financial Management LLC acquired a new position in Immix Biopharma in the 2nd quarter valued at approximately $56,000. Allworth Financial LP acquired a new position in Immix Biopharma in the 2nd quarter valued at approximately $75,000. Everhart Financial Group Inc. purchased a new stake in Immix Biopharma in the 2nd quarter worth approximately $103,000. Finally, Kera Capital Partners Inc. purchased a new stake in Immix Biopharma in the 4th quarter worth approximately $68,000. Institutional investors and hedge funds own 11.26% of the company’s stock.
About Immix Biopharma
Immix Biopharma, Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for cancer and autoimmune diseases. The company focuses on treatments designed to target disease-associated cells and address serious conditions with limited therapeutic options.
Its lead product candidate is NXC-201, an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). NXC-201 is being investigated for relapsed or refractory AL amyloidosis and multiple myeloma, two diseases involving abnormal plasma cells.
Featured Stories
- Five stocks we like better than Immix Biopharma
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
- Meta’s Muse Is Taking Aim at E-Commerce, But Amazon Isn’t Playing Along
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
